Strategies to target the cancer driver MYC in tumor cells

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The MYC oncoprotein is a key regulator of cellular transcription, DNA replication, and cell cycle, crucial for proliferation, growth, differentiation, and apoptosis.
• Aberrant MYC activation is a major driver in most human cancers, making it a significant therapeutic target.
• Directly inhibiting MYC is challenging due to its non-enzymatic functions and unstructured surface, necessitating indirect inhibition strategies.

Purpose of the Study:

• To provide an overview of direct and indirect MYC-inhibiting agents and their mechanisms of action.
• To summarize current drug delivery technologies for targeting MYC-dependent cancer cells.
• To highlight the importance of effective drug formulations for MYC-targeted cancer therapy.

Main Methods:

• Review of existing literature on MYC inhibitors and drug delivery systems.
• Analysis of preclinical and early-stage clinical studies of MYC-targeting agents.
• Examination of viral vectors and nanoparticle-based delivery technologies.

Main Results:

• Multiple organic compounds, nucleic acids, and peptides targeting MYC are in early development, but none are approved for clinical use.
• Drug delivery technologies, including viral vectors and nanoparticles, are emerging for targeting MYC-dependent tumors.
• Achieving high intracellular concentrations of MYC inhibitors is critical for therapeutic success.

Conclusions:

• Indirect inhibition of MYC is a promising strategy for cancer therapy.
• Development of efficient drug delivery systems is essential for the clinical translation of MYC inhibitors.
• Optimizing drug formulation and delivery is as crucial as discovering novel MYC-inhibiting agents.